Education
About Us
Working with TipRanks
Follow Us
Abbott Laboratories (ABT)
:ABT
ABT Stock Chart & Stats
Day’s Range― - ―
52-Week Range$99.71 - $141.23
Previous CloseN/A
Volume1.03M
Average Volume (3M)7.81M
Market Cap
$220.05B
Enterprise Value$205.04B
Total Cash (Recent Filing)$1.57B
Total Debt (Recent Filing)$17.33B
Price to Earnings (P/E)16.6
Beta0.39
Next Earnings
Apr 16, 2025EPS Estimate
1.07Last Dividend Ex-Date
Apr 15, 2025Dividend Yield1.76%
Share Statistics
EPS (TTM)7.66
Shares Outstanding1,734,323,400
10 Day Avg. Volume8,402,568
30 Day Avg. Volume7,805,523
Financial Highlights & Ratios
PEG Ratio0.12
Price to Book (P/B)N/A
Price to Sales (P/S)5.22
Price to Cash Flow (P/CF)19.10
P/FCF Ratio19.10
Enterprise Value/Market Cap0.93
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit8.82
Enterprise Value/Ebitda18.86
Forecast
1Y Price Target
$140.21Price Target Upside10.51% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering16
---
Bulls Say, Bears Say
Bulls Say
Clinical Outcomes And Product EfficacyThe newly released two-year results reveal a statistically significant reduction in heart failure hospitalizations for severe TR patients treated with TriClip compared to those on medical therapy alone.
Financial Performance And GrowthThe company's organic core revenue growth of 10.1% last quarter was driven by above-consensus Med Devices growth of 14.0%.
New Products And CommercializationABT has multiple new products that are rolling out now or in the early stages of commercialization, including TriClip in the US and Volt in Europe.
Bears Say
Legal IssuesThe overturned state case is viewed as incrementally negative for Abbott Laboratories as easing concerns around NEC litigation had previously helped drive the stock up.
Market Competition And AdoptionThe uptake of PFA OUS is not anywhere close to what it is in the US.
---
Ownership Overview
0.48% Insiders
24.98% Mutual Funds
21.76% Other Institutional Investors
32.65% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ABT FAQ
What was Abbott Laboratories’s price range in the past 12 months?
Abbott Laboratories lowest stock price was $99.71 and its highest was $141.23 in the past 12 months.
What is Abbott Laboratories’s market cap?
Abbott Laboratories’s market cap is $220.05B.
When is Abbott Laboratories’s upcoming earnings report date?
Abbott Laboratories’s upcoming earnings report date is Apr 16, 2025 which is tomorrow.
How were Abbott Laboratories’s earnings last quarter?
Abbott Laboratories released its earnings results on Jan 22, 2025. The company reported $1.34 earnings per share for the quarter, beating the consensus estimate of $1.336 by $0.004.
Is Abbott Laboratories overvalued?
According to Wall Street analysts Abbott Laboratories’s price is currently Undervalued.
Does Abbott Laboratories pay dividends?
Abbott Laboratories pays a Quarterly dividend of $0.589 which represents an annual dividend yield of 1.76%. See more information on Abbott Laboratories dividends here
What is Abbott Laboratories’s EPS estimate?
Abbott Laboratories’s EPS estimate is 1.07.
How many shares outstanding does Abbott Laboratories have?
Abbott Laboratories has 1,734,323,400 shares outstanding.
What happened to Abbott Laboratories’s price movement after its last earnings report?
Abbott Laboratories reported an EPS of $1.34 in its last earnings report, beating expectations of $1.336. Following the earnings report the stock price went up 0.848%.
Which hedge fund is a major shareholder of Abbott Laboratories?
Currently, no hedge funds are holding shares in ABT
---
Abbott Labs Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$140.21 (10.51% Upside)
$140.21 (10.51% Upside)
Blogger Sentiment
Bullish
ABT Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 5.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $80.4M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 0.8%
Last 30 Days ▼ 0.1%
Last 30 Days ▼ 0.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
16.16%
12-Months-Change
Fundamentals
Return on Equity
30.95%
Trailing 12-Months
Asset Growth
11.20%
Trailing 12-Months
Company Description
Abbott Laboratories
Abbott Laboratories (ABT) is a global healthcare company based in the United States, specializing in the development, manufacture, and sale of a diverse range of health care products. The company operates through four main business segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. Abbott is known for its wide array of offerings, including nutritional products such as Similac and Ensure, diagnostic systems like the Architect and Alinity platforms, medical devices for cardiovascular and neuromodulation therapies, and a robust portfolio of branded generic pharmaceuticals. The company serves customers in more than 160 countries, providing solutions aimed at improving health outcomes across the globe.
---
ABT Company Deck
---
ABT Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted strong growth across several segments, particularly in medical devices and adult nutrition, alongside effective financial management and strategic guidance for 2025. However, challenges such as foreign exchange impacts, market dynamics in China, and an increased tax rate were noted.Read More>---
ABT Net sales Breakdown
45.26% Medical Devices
22.27% Diagnostic Products
20.05% Nutritional Products
12.38% Established Pharmaceutical Products
0.04% Other
---
ABT Stock 12 Month Forecast
Average Price Target
$140.21
▲(10.51% Upside)
Technical Analysis
Best Analysts Covering ABT
1 Year
1 Year Success Rate
24/25 ratings generated profit
1 Year Average Return
+20.28%
assigned a buy rating 3 months ago
Copying Rick Wise's trades and holding each position for 1 Year would result in 96.00% of your transactions generating a profit, with an average return of +20.28% per trade.
---